VTAK 8-K: Q3 & nine-month 2025 results press release furnished

Rhea-AI Filing Summary

Catheter Precision, Inc. (VTAK) reported that it furnished a press release announcing financial results for the three and nine months ended September 30, 2025. The company provided this update under Item 2.02 of the Exchange Act.

The press release is included as Exhibit 99.1 and, as stated, the information is being furnished and not deemed filed under Section 18. VTAK’s common stock trades on NYSE American.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

false 0001716621 0001716621 2025-11-13 2025-11-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

___________________

FORM 8-K

___________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):

November 13, 2025

___________________

Catheter Precision, Inc.

(Exact name of registrant as specified in its charter)

___________________

Delaware		001-38677		38-3661826
(State or other jurisdiction of incorporation)		(Commission File Number)		(IRS Employer Identification No.)

1670 Highway 160 West

Suite 205

Fort Mill, SC 29708

(Address of principal executive offices, including zip code)

(973) 691-2000

(Registrant’s telephone number, including area code)

N/A

(Former name or former address, if changed since last report.)

___________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.0001 per share	VTAK	NYSE American

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Condition.

On November 13, 2025, Catheter Precision, Inc. (the “Company”) issued a press release announcing its financial results for the three and nine months ended September 30, 2025.  The full text of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities and Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section.  The information in this Current Report on Form 8-K shall not be incorporated by reference into any registration statement or other document filed with the Securities and Exchange Commission, whether filed before or after the date hereof regardless of any general incorporation language in any such filing, unless the registrant expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

Exhibit		Description
99.1		Press Release Issued on November 13, 2025
104		Cover Page Interactive Data File (formatted as inline XBRL)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

		CATHETER PRECISION, INC.
Date:	November 14, 2025	By:	/s/ Philip Anderson
			Philip Anderson
			Chief Financial Officer

FAQ

What did Catheter Precision (VTAK) announce in this 8-K?

It furnished a press release with financial results for the three and nine months ended September 30, 2025 under Item 2.02.

Which exhibit contains the financial results press release for VTAK?

Exhibit 99.1 contains the press release issued on November 13, 2025.

Is the financial information in this 8-K considered filed?

No. The information is being furnished and shall not be deemed filed under Section 18 of the Exchange Act.

What is VTAK’s stock exchange and ticker?

Common stock trades on NYSE American under the ticker VTAK.

What additional exhibit is included?

Exhibit 104, the Cover Page Interactive Data File formatted as inline XBRL.

Which period do the results cover?

The three and nine months ended September 30, 2025.